SoftMedx Healthcare Limited (0648) Fair Value & Analysis
Healthcare · HK · Market cap HK$646M
Fair value as of: Aug 13, 2026
From 23 valuation models · updated 2 days ago
Share price −22.1% over the past month.
A solid business, but screening 79% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.1615). The favourable scenario is already priced in.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (HK$0.0850 to HK$0.1615) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.1720 – HK$22.40 · fair‑value band HK$0.0850 – HK$0.1615 · the HK$0.6000 price screens above the HK$0.1275 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
SoftMedx Healthcare Limited (0648) currently trades at HK$0.6000, while our model-based Fair Value estimate is HK$0.1275, implying the stock looks roughly 78.8% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, SoftMedx Healthcare Limited generated revenue of HK$68.2M at a net margin of 10.2%. Revenue grew 35.7% year over year. It earns a return on equity of 46.6%. The stock trades on a trailing P/E of 25.1 (as of Jul 2, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.0850 (bear case) to HK$0.1615 (bull case); at HK$0.6000, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -79%, 0648 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (HK$0.3000) versus Asset-Based (HK$0.0200). Highest evidence: Growth DCF (80).
Notify me when 0648 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SoftMedx Healthcare Limited, an investment holding company, through its subsidiary, Wah Yan Bright Healthcare Limited, engages in the medical and well-being business for distribution of medical and healthcare equipment and products in Hong Kong.
Full company description
SoftMedx Healthcare Limited, an investment holding company, through its subsidiary, Wah Yan Bright Healthcare Limited, engages in the medical and well-being business for distribution of medical and healthcare equipment and products in Hong Kong. The company was formerly known as China Wah Yan Healthcare Limited and changed its name to SoftMedx Healthcare Limited in March 2023. The company was incorporated in 1989 and is based in Wan Chai, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SoftMedx Healthcare Limited reported revenue of HK$68.2M in FY2025 versus HK$1.7M in FY2021, a compound +151.7%/yr. Reported net income was HK$7.0M in FY2025.
0648 screens 79% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 265 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare SoftMedx Healthcare Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SoftMedx Healthcare Limited (0648) overvalued or undervalued?
What is the fair value of 0648?
What is the quality score of 0648?
What is the revenue of SoftMedx Healthcare Limited (0648)?
What is the net profit margin of 0648?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SoftMedx Healthcare Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.